TOLMAR
VC Fund
Fort Collins, United States
TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology products.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries TOLMAR invests in
Stages TOLMAR invests in
Countries TOLMAR invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 1 (50%)
- Medical Device 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Post-IPO Equity 1 (50%)
- Venture - Series Unknown 1 (50%)
Country
- Israel 1 (50%)
- Finland 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anil D'souza
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Gerald Wallner
Data Integrity Manager
|
Data Integrity Manager | Total investments: 0 | Find email | |
|
Parker Schabel
Director of Strategy and Planning
|
Director of Strategy and Planning | Total investments: 0 | Find email | |
Ryan Turncliff
Vice President Clinical Development
|
Vice President Clinical Development | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.Since then, numerous preclinical trials have found the technology tobe effective and safe for various indications and anatomic areas.The findings were published in 12 papers in peer-reviewed scientific journals. Today, the company is running its first clinical trial with very promising preliminary results. | $20M / Post-IPO Equity / Jun 03, 2026 | ||
| DelSiTech is a leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biopharmaceuticals and viral vectors. they focus on parenteral and local administration of drug products. | $10.9M / Venture - Series Unknown / Jan 16, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does TOLMAR invest in?
TOLMAR invests primarily in Health Care, Medical Device and Pharmaceutical startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact TOLMAR?
Public channels for TOLMAR include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TOLMAR?
The team at TOLMAR includes Anil D'souza (Chief Executive Officer), Gerald Wallner (Data Integrity Manager) and Parker Schabel (Director of Strategy and Planning). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
